Padma Thiruvengadam - Integra LifeSciences President
| IART Stock | USD 29.38 0.40 1.38% |
President
Ms. Padma Thiruvengadam is Chief Human Resources Officer Corporationrationrate Vice President Strategic Initiatives and Operational Excellence of Integra LifeSciences Holdings Corporationrationration. She is Integras Corporationrationrate Vice President Strategic Initiatives and Operational Excellence and Chief Human Resources Officer. She is responsible for providing leadership in developing and executing human resources strategy in support of the overall business plan and strategic direction of the organization. She is also responsible for Integras strategic initiatives and program management. Ms. Thiruvengadam was appointed Integras Corporationrationrate Vice President Strategic Initiatives and Operational Excellence and Chief Human Resources Officer in August 2014 and appointed Integras Corporationrationrate Vice President in December 2012. Previously from September 2011 to December 2012 Ms. Thiruvengadam served as Integras Chief Human Resources Officer. Prior to joining Integra Ms. Thiruvengadam held several leadership positions at Pfizer Inc. from 2008 to 2011 including Vice President Global Human Resources for Oncology. She led the Wyeth integration globally for oncology and also served as Vice President Oncology AsiaPacificCanada Operations. Prior to joining Pfizer Ms. Thiruvengadam served as a Senior Vice President Human Resources Executive at Bank of America from 2005 to 2007 and as Executive Vice President Human Resource at Loral Skynet Loral Space and Communications from 2001 to 2004
| Age | 49 |
| Address | 1100 Campus Road, Princeton, NJ, United States, 08540 |
| Phone | 609 275 0500 |
| Web | https://www.integralife.com |
Integra LifeSciences Management Efficiency
The company has return on total asset (ROA) of 0.0424 % which means that it generated a profit of $0.0424 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0399 %, meaning that it created $0.0399 on every $100 dollars invested by stockholders. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.04 in 2024. Return On Capital Employed is likely to gain to 0.05 in 2024. At this time, Integra LifeSciences' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2 B in 2024, whereas Total Current Liabilities is likely to drop slightly above 158.9 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jeffery Doster | HealthStream | 51 | |
| Frode Jensen | HealthEquity | 64 | |
| Larry Trittschuh | HealthEquity | 52 | |
| Ashley Dreier | HealthEquity | 44 | |
| Michael Collier | HealthStream | 48 | |
| Scott McQuigg | HealthStream | 50 | |
| Angelique Hill | HealthEquity | 55 | |
| Mollie Condra | HealthStream | N/A | |
| Michael Sousa | HealthStream | 55 | |
| Gary Robinson | HealthEquity | 55 | |
| Jeffrey Cunningham | HealthStream | 57 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Edward Pearson | HealthStream | 61 | |
| Kevin Karas | National Research Corp | 60 | |
| Delano Ladd | HealthEquity | 43 | |
| Thomas Schultz | HealthStream | 49 | |
| William Otten | HealthEquity | 52 | |
| Edward Bloomberg | HealthEquity | 41 | |
| Steven Jackson | National Research Corp | 42 | |
| Trisha Coady | HealthStream | 48 | |
| Jonathan Soldan | HealthEquity | 32 | |
Management Performance
| Return On Equity | 0.0399 | ||||
| Return On Asset | 0.0424 |
Integra LifeSciences Leadership Team
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Padma Thiruvengadam, Chief Human Resources Officer, Corporate Vice President | ||
| Michael Beaulieu, IR Contact Officer | ||
| Lea Knight, Executive CFO | ||
| Richard Caruso, Founder and Director | ||
| James Sullivan, Independent Director | ||
| Sravan Emany, Vice President Treasurer and Investor Relations | ||
| William Compton, Chief VP | ||
| Christian Schade, Independent Director | ||
| Jeffrey Mosebrook, Principal Accounting Officer, Vice President Corporate Controller | ||
| Susan Krause, Corporate Officer | ||
| Jan Witte, CEO President | ||
| Laurene Isip, Vice Relations | ||
| Raymond Murphy, Independent Director | ||
| Keith Bradley, Independent Director | ||
| Stuart Essig, Chairman of the Board | ||
| Donald Morel, Independent Director | ||
| Jessica Smith, Corporate Officer | ||
| Barbara Hill, Independent Director | ||
| Stephen Leonard, Corporate Chain | ||
| Kenneth Burhop, Chief Scientific Officer, Corporate Vice President | ||
| Ruth Fleming, Vice Marketing | ||
| Eric Schwartz, Corporate Vice President General Counsel, Secretary | ||
| Mathieu Aussermeier, Investor Finance | ||
| Joseph Vinhais, Corporate Vice President - Global Quality Assurance | ||
| Richard Gorelick, Corporate VP of Admin., General Counsel and Secretary | ||
| Lisa Evoli, Corporate Vice President Chief Human Resources Officer | ||
| Robert Davis, President of Specialty Surgical Solutions and Corporate VP | ||
| Maria Platsis, Sr Devel | ||
| Lloyd Howell, Independent Director | ||
| Judith OGrady, Corporate Vice President - Global Regulatory Affairs, Corporate Compliance Officer | ||
| Stuart Hart, Corporate Officer | ||
| Angela Steinway, IR Contact Officer | ||
| Mark Jesser, Corporate Officer | ||
| Deborah Leonetti, Corporate Vice President and Presidentident, Instruments | ||
| Michael McBreen, Executive Surgical | ||
| Carrie Anderson, CFO and Principal Financial Officer, Corporate Vice President | ||
| Peter Arduini, CEO and President Director and Member of Special Award Committee | ||
| Mark Augusti, Corporate Vice President and Presidentident, Orthopedics and Tissue Technologies | ||
| Rhonda Ballintyn, Independent Director | ||
| John Mooradian, Corporate VP of Global Operations and Supply Chain | ||
| Glenn Coleman, CFO, Principal Accounting Officer and Corporate VP | ||
| Daniel Reuvers, Corporate Vice President and Presidentident - International |
Integra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integra LifeSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0399 | ||||
| Return On Asset | 0.0424 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 3.64 B | ||||
| Shares Outstanding | 78.6 M | ||||
| Shares Owned By Insiders | 13.80 % | ||||
| Shares Owned By Institutions | 88.93 % | ||||
| Number Of Shares Shorted | 2.09 M | ||||
| Price To Earning | 26.94 X |
Integra LifeSciences Investors Sentiment
The influence of Integra LifeSciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Integra. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Integra LifeSciences' public news can be used to forecast risks associated with an investment in Integra. The trend in average sentiment can be used to explain how an investor holding Integra can time the market purely based on public headlines and social activities around Integra LifeSciences Holdings. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Integra LifeSciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Integra LifeSciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Integra LifeSciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Integra LifeSciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Integra LifeSciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Integra LifeSciences' short interest history, or implied volatility extrapolated from Integra LifeSciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Integra LifeSciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Integra Stock analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Integra LifeSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integra LifeSciences. If investors know Integra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integra LifeSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.60) | Earnings Share 0.84 | Revenue Per Share 19.248 | Quarterly Revenue Growth (0) | Return On Assets 0.0424 |
The market value of Integra LifeSciences is measured differently than its book value, which is the value of Integra that is recorded on the company's balance sheet. Investors also form their own opinion of Integra LifeSciences' value that differs from its market value or its book value, called intrinsic value, which is Integra LifeSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integra LifeSciences' market value can be influenced by many factors that don't directly affect Integra LifeSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integra LifeSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Integra LifeSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integra LifeSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.